Skip to main content
Erschienen in: Lung 1/2020

10.12.2019 | SLEEP

Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea with Schizophrenia

verfasst von: Marwan Saoud, Musa Saeed, Sumit Patel, M. Jeffery Mador

Erschienen in: Lung | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To determine the 1-year and 3-year adherence rates with Positive Airway Pressure (PAP) therapy in patients with schizophrenia compared to matched controls.

Methods

A case–control retrospective analysis was performed in a Veterans Affairs hospital. All symptomatic patients with schizophrenia ever started on PAP therapy between 2007 and 2015 were compared with controls matched for severity of sleep apnea based on AHI, BMI, and age at the time of diagnosis.

Results

Total number of subjects in both groups was 39. Mean AHI among cases and controls was 27.63 ± 22.16 and 33.59 ± 44.04 (p = 0.32), mean BMI was 34.91 ± 5.87 and 33.92 ± 5.21 (p = 0.43), and mean age at diagnosis was 53.6 ± 11.75 and 55.97 ± 11.92 (p = 0.36), respectively. There was no statistically significant difference in PAP use between patients with schizophrenia and controls at 1-year (percent days device use > 4 h—36.43% ± 31.41 vs. 49.09% ± 38.76; p = 0.17) and 3-year (percent days device use > 4 h—42.43 ± 35.50 vs. 60.53 ± 38.56; p = 0.089) visits

Conclusions

PAP adherence and usage is not significantly different among patients with schizophrenia compared to matched controls. Therefore, schizophrenia does not appear to influence CPAP compliance.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR (2014) Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med 10(4):355–362CrossRef Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR (2014) Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med 10(4):355–362CrossRef
2.
Zurück zum Zitat Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, Hamilton GS, Dharmage SC (2017) Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev 34:70–81CrossRef Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, Hamilton GS, Dharmage SC (2017) Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev 34:70–81CrossRef
3.
Zurück zum Zitat Kribbs NB, Pack AL, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry JN, Getsy JE, Dinges DF (1993) Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 147:887–895CrossRef Kribbs NB, Pack AL, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry JN, Getsy JE, Dinges DF (1993) Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 147:887–895CrossRef
4.
Zurück zum Zitat World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva
5.
Zurück zum Zitat Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63(10):892–909CrossRef Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63(10):892–909CrossRef
6.
Zurück zum Zitat MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK (2018) Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry 9:622CrossRef MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK (2018) Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry 9:622CrossRef
7.
Zurück zum Zitat Myles H, Myles N, Antic NA, Adams R, Chandratilleke M, Liu D, Mercer J, Vakulin A, Vincent A, Wittert G, Galletly G (2016) Obstructive sleep apnea and schizophrenia: a systematic review to inform clinical practice. Schizophrenia Res 170:222–225CrossRef Myles H, Myles N, Antic NA, Adams R, Chandratilleke M, Liu D, Mercer J, Vakulin A, Vincent A, Wittert G, Galletly G (2016) Obstructive sleep apnea and schizophrenia: a systematic review to inform clinical practice. Schizophrenia Res 170:222–225CrossRef
8.
Zurück zum Zitat Sugishita K, Yamasue H, Kasai K (2010) Continuous positive airway pressure for obstructive sleep apnea improved negative symptoms in a patient with schizophrenia. Psychiatry Clin Neurosci 64:665CrossRef Sugishita K, Yamasue H, Kasai K (2010) Continuous positive airway pressure for obstructive sleep apnea improved negative symptoms in a patient with schizophrenia. Psychiatry Clin Neurosci 64:665CrossRef
9.
Zurück zum Zitat Boufidis S, Kosmidis MH, Bozikas VP, Daskalopoulou-Vlahoyianni E, Pitsavas S, Karavatos A (2003) Treatment outcome of obstructive sleep apnea syndrome in a patient with schizophrenia: case report. Int J Psychiatry Med 33(3):305–310CrossRef Boufidis S, Kosmidis MH, Bozikas VP, Daskalopoulou-Vlahoyianni E, Pitsavas S, Karavatos A (2003) Treatment outcome of obstructive sleep apnea syndrome in a patient with schizophrenia: case report. Int J Psychiatry Med 33(3):305–310CrossRef
10.
Zurück zum Zitat Grunstein PF, Fazleen A, Sankaran P (2017) Schizophrenia and obstructive sleep apnea: could CPAP cure both? Am J Respir Crit Care Med 195:A2597 Grunstein PF, Fazleen A, Sankaran P (2017) Schizophrenia and obstructive sleep apnea: could CPAP cure both? Am J Respir Crit Care Med 195:A2597
11.
Zurück zum Zitat Hiraoka T, Yamada N (2013) Treatment of psychiatric symptoms in schizophrenia spectrum disorders with comorbid sleep apnea syndrome: a case report. Seishin Shinkeigaku Zasshi 115(2):139–146 (in Japanese) PubMed Hiraoka T, Yamada N (2013) Treatment of psychiatric symptoms in schizophrenia spectrum disorders with comorbid sleep apnea syndrome: a case report. Seishin Shinkeigaku Zasshi 115(2):139–146 (in Japanese) PubMed
12.
Zurück zum Zitat Owen-Smith A, Stewart C, Green C, Ahmedani BK, Waitzfelder BE, Rossom R, Copeland LA, Simon GE (2016) Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness. Gen Hosp Psychiatry 38:9–14CrossRef Owen-Smith A, Stewart C, Green C, Ahmedani BK, Waitzfelder BE, Rossom R, Copeland LA, Simon GE (2016) Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness. Gen Hosp Psychiatry 38:9–14CrossRef
13.
Zurück zum Zitat Nelson LA, Graham MR, Lindesy CC, Rasu RS (2011) Adherence to antihyperlipidemic medication and lipid control in diabetic veterans affairs patients with psychotic disorders. Psychomatics 52:310–318CrossRef Nelson LA, Graham MR, Lindesy CC, Rasu RS (2011) Adherence to antihyperlipidemic medication and lipid control in diabetic veterans affairs patients with psychotic disorders. Psychomatics 52:310–318CrossRef
14.
Zurück zum Zitat Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Igancio RV, Valenstein M (2010) Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophrenia Bull 36(2):428–435CrossRef Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Igancio RV, Valenstein M (2010) Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophrenia Bull 36(2):428–435CrossRef
Metadaten
Titel
Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea with Schizophrenia
verfasst von
Marwan Saoud
Musa Saeed
Sumit Patel
M. Jeffery Mador
Publikationsdatum
10.12.2019
Verlag
Springer US
Erschienen in
Lung / Ausgabe 1/2020
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-019-00302-8

Weitere Artikel der Ausgabe 1/2020

Lung 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.